Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Cancer Research
|
February 12, 2005
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451
W Gregory Roberts, Pamela M Whalen, Erik Soderstrom, et al.
Journal of Medicinal Chemistry
|
November 8, 2017
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
Stefano Crosignani, Patrick Bingham, Pauline Bottemanne, et al.
Journal of Medicinal Chemistry
|
March 31, 2011
Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors
Ted W Johnson, Steven P Tanis, Scott L Butler, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 16, 2013
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolites
Sajiv K Nair, Jean J Matthews, Stephan J Cripps, et al.
Molecular Cancer Therapeutics
|
September 21, 2018
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Bruno Gomes, Gregory Driessens, Derek Bartlett, et al.
Journal of Medicinal Chemistry
|
February 11, 2026
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma
Deborah S Mortensen, Hunter P Shunatona, Natalie Holmberg-Douglas, et al.
Journal of Medicinal Chemistry
|
July 10, 2026
Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365
Deborah S Mortensen, Surendra Nayak, Veronique Plantevin-Krenitsky, et al.
Journal of Medicinal Chemistry
|
March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR
Simon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Journal of Medicinal Chemistry
|
January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants
Hengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Cancer Research
|
February 12, 2005
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451
W Gregory Roberts, Pamela M Whalen, Erik Soderstrom, et al.
Journal of Medicinal Chemistry
|
November 8, 2017
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
Stefano Crosignani, Patrick Bingham, Pauline Bottemanne, et al.
Journal of Medicinal Chemistry
|
March 31, 2011
Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors
Ted W Johnson, Steven P Tanis, Scott L Butler, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 16, 2013
N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolites
Sajiv K Nair, Jean J Matthews, Stephan J Cripps, et al.
Molecular Cancer Therapeutics
|
September 21, 2018
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Bruno Gomes, Gregory Driessens, Derek Bartlett, et al.
Journal of Medicinal Chemistry
|
February 11, 2026
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma
Deborah S Mortensen, Hunter P Shunatona, Natalie Holmberg-Douglas, et al.
Journal of Medicinal Chemistry
|
July 10, 2026
Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365
Deborah S Mortensen, Surendra Nayak, Veronique Plantevin-Krenitsky, et al.
Journal of Medicinal Chemistry
|
March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR
Simon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Journal of Medicinal Chemistry
|
January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants
Hengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Page
of 5